Inotiv Announces Pricing Of Public Offering Of 6M Common Shares Of Common Stock At A Price Of $4.25/Share
Inotiv Announces Pricing Of Public Offering Of 6M Common Shares Of Common Stock At A Price Of $4.25/Share
Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced the pricing of its underwritten public offering of 6,000,000 common shares at a price to the public of $4.25 per share. In addition, the Company has granted the underwriter a 30-day option to purchase up to an additional 900,000 common shares at the public offering price less underwriting discounts and commissions. All the shares are being offered by the Company. The offering is expected to close on December 19, 2024, subject to customary closing conditions.
Inotiv, Inc.（纳斯达克股票代码：NOTV）（“公司”）是一家领先的合同研究机构，专门从事非临床和分析药物发现与开发服务以及研究模型及相关产品和服务，今天宣布其承销公开发行6,000,000股普通股的定价，向公众公开发行的价格为每股4.25美元。此外，公司还授予承销商30天的期权，允许其按公开发行价格减去承销折扣和佣金再购买最多90万股普通股。所有股票均由公司发行。此次发行预计将于2024年12月19日结束，但须遵守惯例成交条件。
The Company intends to use the net proceeds from this offering for working capital, capital expenditures and other general corporate purposes.
公司打算将本次发行的净收益用于营运资金、资本支出和其他一般公司用途。
Lake Street Capital Markets, LLC is acting as the sole book-running manager for the proposed offering.
Lake Street Capital Markets, LLC是本次拟议发行的唯一账面管理公司。
